Status:
RECRUITING
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Lead Sponsor:
Kaiser Permanente
Collaborating Sponsors:
Seqirus
Conditions:
Influenza
Community-acquired Pneumonia
Eligibility:
All Genders
65+ years
Brief Summary
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in pr...
Eligibility Criteria
Inclusion
- Age ≥65 years at the time of influenza vaccination
- KPNC member at the time of vaccination
- Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons
Exclusion
- Age \<65 years at the time of influenza vaccination
- Received either aIIV4 or HD-IIV4 in the inpatient setting
- Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
- Receive an influenza vaccination outside of KPNC
Key Trial Info
Start Date :
August 17 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
960000 Patients enrolled
Trial Details
Trial ID
NCT06029933
Start Date
August 17 2023
End Date
May 1 2026
Last Update
September 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente Northern California (entire region)
Oakland, California, United States, 94612